---

---

approved   entities : Eli lilly and company   

save search

---

FDA Delays Approval of Donanemab for the Treatment of Early-Stage Alzheimer’sAgency to convene an advisory committee to consider the drug
Published: 2024-03-08 (Crawled : 15:30) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| -3.77% | O: -0.02% H: 0.0% C: -2.29%
fda drug approval treatment

---

Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| Email alert Add to watchlist
jaypirca fda approved treatment leukemia

---

Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-17 (Crawled : 18:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| -52.98% | O: -1.71% H: 0.0% C: 0.0%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 27.52% | O: 0.49% H: 0.0% C: 0.0%
ebglyss dermatitis approval

---

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Published: 2023-11-08 (Crawled : 21:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 25.14% | O: 1.29% H: 3.0% C: 1.89%
fda obesity treatment medical tirzepatide

---

FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis
Published: 2023-10-26 (Crawled : 23:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 30.2% | O: -2.09% H: 0.0% C: 0.0%
fda active treatment

---

U.S. Food and Drug Administration (FDA) Approves FoundationOne®CDx as a Companion Diagnostic for Lilly’s Retevmo® (selpercatinib) for Certain Patients with Solid Tumors
Published: 2023-10-09 (Crawled : 18:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 32.83% | O: -0.21% H: 2.8% C: 1.37%
foundationone drug diagnostic food tumors companion

---

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease
Published: 2023-09-22 (Crawled : 15:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 32.8% | O: -2.93% H: 1.22% C: 0.32%
jardiance fda disease kidney treatment

---

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer
Published: 2023-08-22 (Crawled : 12:20) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 37.03% | O: 0.3% H: 1.19% C: 0.75%
retevmo approved cancer thyroid

---

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease
Published: 2023-07-25 (Crawled : 13:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 63.45% | O: -0.34% H: 0.69% C: -0.05%
jardiance disease kidney approved treatment

---

US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older
Published: 2023-06-21 (Crawled : 22:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 66.12% | O: 0.56% H: 0.18% C: -0.33%
jardiance fda children treatment diabetes

---

Global Axial Spondyloarthritis Treatment Market to 2027: Increase in the Number of Approved Biosimilars Fuels the Sector
Published: 2023-06-16 (Crawled : 02:00) - prnewswire.com
UCBJY | $63.676 7.2K |

Manufacturing

| 37.7% | O: 1.21% H: 0.0% C: -0.2%
PFE A | $25.81 1.65% 15M |

Health Technology

| -36.05% | O: 0.28% H: 1.25% C: 0.5%
JNJ | News | $147.17 0.98% 3.2M |

Health Technology

| -11.47% | O: 0.46% H: 0.31% C: -0.15%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 65.39% | O: 0.41% H: 0.26% C: -1.77%
BMY | $48.58 0.58% 2.6M |

Health Technology

| -25.31% | O: 0.32% H: 2.1% C: 1.97%
approved treatment global market

---

U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for Pfizer’s BRAFTOVI® (encorafenib)
Published: 2023-06-09 (Crawled : 12:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 68.46% | O: 0.82% H: 0.0% C: -0.73%
foundationone drug diagnostic food companion

---

The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy
Published: 2023-05-10 (Crawled : 00:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 75.26% | O: -0.54% H: 2.89% C: 2.31%
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| -17.35% | O: -1.75% H: 0.0% C: 0.0%
INCY | $52.45 -0.7% 530K |

Health Technology

| -18.45% | O: 0.29% H: 0.07% C: -1.6%
tyvyt china therapy

---

Non-steroidal Anti-inflammatory Drugs Market Report 2023: Quick Authority Approvals by Governments and Increase in Government Initiatives Presents Opportunities
Published: 2023-04-27 (Crawled : 00:00) - prnewswire.com
GLAXF | $20.2 510 |

Health Technology

| 14.12% | O: 0.23% H: 0.0% C: 0.0%
SNYNF | News | $92.7 600K |

Health Technology

| -16.75% | O: -1.21% H: 0.12% C: -2.76%
AZNCF | $138.24 800 |

Health Technology

| -7.33% | O: -0.41% H: 0.79% C: 0.79%
RBGLY | $10.35 990K |

Manufacturing

| -35.69% | O: 2.25% H: 0.31% C: 0.06%
PRGO | $30.49 1.84% 350K |

Health Technology

| -17.99% | O: 0.11% H: 1.61% C: 1.42%
JNJ | News | $147.17 0.98% 3.2M |

Health Technology

| -11.07% | O: -0.12% H: 0.58% C: 0.55%
GSK | $39.605 0.85% 790K |

Health Technology

| 9.97% | O: -0.25% H: 0.97% C: 0.31%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 92.33% | O: 1.96% H: 1.59% C: -0.54%
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| -18.34% | O: -2.09% H: 0.0% C: 0.0%
AZN | $68.3 -0.09% 2M |

Health Technology

| -7.47% | O: -1.03% H: 1.02% C: 0.28%
report market

---

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
Published: 2023-04-20 (Crawled : 12:20) - biospace.com/
BWV | $0.1802 5.44% 530K |

| -83.37% | O: 1.51% H: 2.73% C: -2.73%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 102.65% | O: 0.25% H: 1.26% C: 0.92%
VERU | $1.365 -3.87% 1.7M |

Health Technology

| 37.86% | O: 2.91% H: 16.04% C: 13.21%
entadfi water acquisition blue

---

Global Biosimilars Business and Investment Opportunities 2023: Attractive Approval Numbers Present Fertile Ground for New Entrants
Published: 2023-04-18 (Crawled : 18:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 101.63% | O: 0.17% H: 0.34% C: -0.83%
CHRS | $1.995 -0.25% 2M |

Health Technology

| -73.88% | O: 0.73% H: 0.0% C: -1.45%
BIIB | $192.68 1.13% 590K |

Health Technology

| -33.21% | O: 0.05% H: 0.77% C: 0.5%
business approval global

---

U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor
Published: 2023-01-27 (Crawled : 20:00) - biospace.com/
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 115.73% | O: -0.55% H: 0.57% C: -1.16%
fda

---

U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
Published: 2023-01-19 (Crawled : 00:00) - prnewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 113.85% | O: -1.16% H: 0.6% C: -0.27%
drug approval response food

---

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List
Published: 2023-01-19 (Crawled : 04:00) - prnewswire.com
SNYNF | News | $92.7 600K |

Health Technology

| -4.71% | O: 1.26% H: 1.19% C: 1.19%
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 113.28% | O: 0.1% H: 0.97% C: -0.37%
SNY | News | $46.545 2.55% 2.3M |

Health Technology

| -8.54% | O: -0.92% H: 0.0% C: 0.0%
drug approved

---

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy
Published: 2022-12-19 (Crawled : 12:00) - globenewswire.com
LLY | $728.765 -2.3% 1.5M |

Health Technology

| 108.62% | O: -0.57% H: 0.53% C: -0.01%
EGRX | $4.69 4.69% 19K |

Health Technology

| -84.01% | O: 3.31% H: 0.46% C: -0.89%
pemfexy fda pharmaceuticals approval

---

Gainers vs Losers

74%

26%

Top 10 Gainers

AGBA | News | $1.27 217.5% 120M |

Finance

EGOX | $0.054 50.0% 290M |

INDO | $5.43 33.09% 10M |

Energy Minerals

NVFY | $2.71 28.44% 31M |

Consumer Durables

ZCMD | $1.86 28.28% 29M |

Commercial Services

BSFC | $0.0822 27.64% 75M |

Manufacturing

RWOD | $10.08 26.05% 5.6M |

n/a

CHRO | $1.53 24.9% 100K |

n/a

HUSA 4 | $2.07 23.95% 2.1M |

Energy Minerals

INSG | $2.98 23.14% 190K |

Electronic Technology

---

Your saved searches

---